Barclays analyst Carter Gould lowered the firm’s price target on Amgen to $225 from $227 and keeps an Underweight rating on the shares following the Q1 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMGN:
- Amgen price target lowered to $288 from $293 at Piper Sandler
- AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
- Amgen raises FY23 adjusted EPS view to $17.60-$18.70 from $17.40-$18.60
- Amgen reports Q1 adjusted EPS $3.98, consensus $3.85
- Notable companies reporting after market close
Questions or Comments about the article? Write to editor@tipranks.com